Techniques in the synthesis of mononuclear manganese complexes: a review

This article describes an overview of the synthetic techniques and protocols for the preparation of new ligands and respective manganese (Mn) complexes to be tested for biomedical applications. Mn is an essential and biocompatible element, the complexes of which have diverse medicinal applications. The most significant use of Mn complexes is their application against reactive oxygen species in biological systems, and due to this, three Mn-incorporated complexes (AEOL-10150, EUK-134, and M40403) are already under clinical trials. Hence, the interest in synthesizing biologically active Mn complexes is rapidly increasing. Mn complexes are commonly synthesized using either water or ethanol as a reaction medium for their possible usage in biological systems. Using common Mn salts along with suitable organic ligand works well in the presence of little heat to obtain Mn complexes of interest.

Pharmacological performance of novel poly-(ionic liquid)-grafted chitosan-N-salicylidene Schiff bases and their complexes

In our endeavor to develop a new class of pharmacological candidates with antimicrobial and anticancer efficacy, a series of biopolymeric chitosan Schiff bases bearing salicylidene ionic liquid (IL-Sal) brushes (ILCSB1-3, poly-(GlcNHAc-GlcNH2-(GlcN-Sal-IL)) was successfully synthesized by adopting efficient synthetic routes. Unfortunately, metalation trials of these biopolymeric Schiff bases afford the corresponding Ag(I)/M(II) complexes (where M=Co, Pd). These designed architectures were structurally characterized and pharmacologically evaluated for their in vitro antimicrobial, against common bacterial and fungal pathogens, and anticancer activities against human colon carcinoma (HCT-116) cell line. In conclusion functionalization of chitosan with IL-Sal brushes coupled with metalation of formed ILCSBs were synergistically enhanced its antimicrobial and antitumor properties to a great extent. Noteworthy, Ag-ILCSB2 (IC50=9.13μg/mL) was ca. 5-fold more cytotoxic against HCT-116 cell line than ILCSB2 (IC50=43.30μg/mL).

Ionic Sal-SG Schiff bases as new synergetic chemotherapeutic candidates: synthesis, metalation with Pd(ii) and in vitro pharmacological evaluation

A series of novelN-(salicylidene)-sulfaguanidines (Sal-SG) bearing ionic liquid (IL) terminals (ILSSGH,4a–f) have been synthesized by Schiff base condensation of IL-functionalized salicylaldehydes (ILSal,3a–g) and sulfaguanidine (SG).